LivaNova’s (LIVN) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of LivaNova (NASDAQ:LIVN) in a report issued on Monday,Benzinga reports. They currently have a $64.00 target price on the stock.

LIVN has been the subject of a number of other reports. Barclays reduced their price target on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating for the company in a research report on Friday, March 7th. The Goldman Sachs Group reduced their price target on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. Wolfe Research cut shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Mizuho reduced their target price on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Finally, Stifel Nicolaus reduced their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $61.17.

LivaNova Price Performance

Shares of LIVN opened at $40.84 on Monday. LivaNova has a 1-year low of $36.85 and a 1-year high of $64.48. The stock has a market cap of $2.22 billion, a PE ratio of 97.24 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The firm has a fifty day moving average price of $45.60 and a 200 day moving average price of $48.89.

Institutional Trading of LivaNova

Several hedge funds have recently bought and sold shares of LIVN. Atria Investments Inc grew its stake in shares of LivaNova by 6.2% in the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after purchasing an additional 331 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in LivaNova in the third quarter valued at approximately $292,000. Segall Bryant & Hamill LLC acquired a new stake in shares of LivaNova in the third quarter worth $2,127,000. Intech Investment Management LLC increased its position in LivaNova by 80.4% during the third quarter. Intech Investment Management LLC now owns 15,815 shares of the company’s stock worth $831,000 after acquiring an additional 7,049 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in LivaNova by 17.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock worth $32,678,000 after acquiring an additional 93,311 shares during the period. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.